Cortechs.ai and EDAP Announce World's First OnQ™ Prostate-Assisted Focal One® Robotic HIFU Procedure at UCSF Prostate Cancer Center

Core Insights - Cortechs.ai and EDAP TMS SA have successfully completed the world's first OnQ Prostate-assisted Focal One® Robotic HIFU procedure at UCSF, marking a significant milestone in prostate cancer treatment [1][6] - OnQ Prostate is the only FDA-cleared solution for RSI-MRI, providing detailed tissue microstructure information to help urologists identify suitable candidates for focal therapy [2][6] - The integration of OnQ Prostate with Focal One enhances lesion localization and targeting, improving the precision of prostate cancer treatments [3][6] Company Overview - Cortechs.ai specializes in AI applications in radiology, focusing on advanced medical imaging technologies to enhance disease screening and early detection [5] - The company develops innovative medical device software for tracking neurodegeneration and prostate cancer, offering cost-effective solutions for assessing prostate health [5] - EDAP TMS SA is recognized for its robotic energy-based therapies, developing minimally invasive medical devices using ultrasound technology, with Focal One being a leading platform for prostate focal therapy [7] Industry Context - Focal therapy is an emerging approach in prostate cancer care aimed at ablating significant disease while preserving healthy tissue, thus reducing side effects associated with whole-gland treatments [3][4] - The ability to precisely localize lesions is critical for urologists to achieve successful oncologic control while minimizing damage to surrounding healthy tissue [3][4] - As focal therapy becomes more integrated into prostate cancer care, companies like Cortechs.ai are at the forefront of developing solutions that support effective, evidence-based, and minimally invasive treatment strategies [4]